Cannabis - Articles - Page 3 | CARLAT PUBLISHING

Clinical Update

Naltrexone: A Jack of All Trades?

April 1, 2023

Julio Cesar Nunes, MD. Psychiatry resident, Yale University. New Haven, CT.

Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University. New Haven, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Nunes and Dr. Capurso have no financial relationships with companies related to this material.

Naltrexone was once hailed as a treatment for all addictive disorders. While the hype has not entirely panned out, it still holds an important place in our armamentarium of addiction treatments. Here, we review the evidence for its use and provide prescribing recommendations.

RESEARCH UPDATE

Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Trial

January 30, 2023

Olaniyi Olayinka, MD.

Olaniyi Olayinka, MD. Dr. Olayinka has no financial relationships with companies related to this material.

Everyone knows that drinking alcohol can impair driving ability. Researchers here demonstrate that driving under the influence of cannabis can be risky as well.

EXPERT Q&A

Medicinal Cannabis

September 1, 2022

Deepak Cyril D’Souza, MD

Deepak Cyril D’Souza, MD. Professor of Psychiatry, Yale University School of Medicine. Psychiatrist, VA Connecticut Healthcare System, New Haven, CT. Dr. D’Souza, expert for this educational activity, has disclosed that he owns stocks in Jazz Pharmaceuticals and Biohaven Pharmaceuticals. Dr. Capurso has reviewed the content of this interview and determined that there is no commercial bias as a result of these financial relationships.

Laws permitting the use of cannabis for medicinal purposes are being passed around the country, but what are we to make of this new and evolving legal patchwork? Dr. D’Souza describes the process and implications of state-specific legislation, and reviews the evidence, or lack thereof, for cannabis treatment of psychiatric disorders.

EXPERT Q&A

Cannabis Use Disorder and Withdrawal

September 1, 2022

Denise Walker, PhD

Denise Walker, PhD. Research Professor and Director of the Innovative Programs Research Group, School of Social Work, University of Washington, Seattle, WA. Co-developer of The Change Companies’ What About Marijuana Journal. Dr. Walker, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Walker reviews the clinical features of cannabis use disorder, who is most at risk, how it is similar and how it differs from other addictions, and treatment approaches. She also describes cannabis withdrawal, a syndrome that can pose a barrier to treatment, but frequently goes unrecognized.

CLINICAL UPDATE

Currently Available Cannabis Products

September 1, 2022

Alex K. Rahimi, MD

Alex K. Rahimi, MD. Addiction Psychiatrist, Fort Belvoir Community Hospital, VA. Assistant Professor of Psychiatry, Uniformed Services University, Bethesda, MD. Dr. Rahimi, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

The sale of medical and recreational cannabis products has become big business as the prevalence of cannabis use increases across the country. There has been an explosion in the number of available products and their potency. Here, we go over what sorts of products are on the market now and what the implications for our patients.

An Off-Label Guide to Gabapentin

January 31, 2022

Rajesh R. Tampi, MD, MS, DFAPA. and Chris Aiken, MD.

Rajesh R. Tampi, MD, MS, DFAPA. Professor of Medicine, Case Western Reserve University. Chairman, Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, and Chief of Geriatric Psychiatry, Cleveland Clinic. Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Off-label gabapentin (Neurontin) got a bad rep when it missed the mark in bipolar disorder, but there may be something worth salvaging in this drug. Here, we weigh its pros and cons for anxiety, substance use disorders, sleep, pain, and hot flashes, and compare it to its underutilized cousin, pregabalin (Lyrica).

Nicotine Patch for Cannabis Withdrawal?

July 3, 2021

John O’Neal, MD.

John O’Neal, MD. Dr. O’Neal has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

As cannabis use becomes more widespread, treaters will inevitably see increases in patients reporting symptoms of cannabis withdrawal. Researchers in this study investigated whether a nicotine patch might help mitigate some of these symptoms. Results were not particularly promising, and should only be considered for patients who also use tobacco.

Cannabis and Kids

December 16, 2019

Child psychiatrists are grappling with the problem of pervasive use of marijuana in an age where legalization of use for adults has led to even greater use in teens. In this episode, Dr. Feder and Mara go over two recent interviews in The Carlat Child Psychiatry Report with Gabriella Gobbi, MD, PhD, of...

Outpatient Management of Opioid Addiction

October 3, 2019

Sandra Gomez-Luna, MD

Sandra Gomez-Luna, MD

Child, adolescent, and adult psychiatrist in Darien, CT. Medical Director of Parent Child Support Center, a subsidiary of Behavioral Health Care (BHcare)

Dr. Gomez-Luna has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The opioid crisis demands that child psychiatrists understand more about outpatient treatment in adolescents as more of us are asked to participate in assessment and treatment planning for this population. In this QA, we discuss some of the well-laid-out approaches for child psychiatrists to manage opioid treatment within the child or teen’s community.

Assessing and Treating Cannabis Use Disorder

October 3, 2019

Gabriella Gobbi, MD, PhD

Gabriella Gobbi, MD, PhD

Professor, Department of Psychiatry, McGill University; Psychiatrist and Clinical Scientist at the McGill University Health Center

Dr. Gobbi has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Child psychiatrists are grappling with the problem of pervasive use of marijuana in an age where legalization of use for adults has led to even greater use in teens. In this QA, we discuss the impact of cannabis, its interaction with depression, and the conundrum of cannabis withdrawal so that child psychiatrists can gain tools for addressing marijuana use and addiction in their outpatient practice.